Dyslipidemia.

Dyslipidemia

Primary Prevention and Statins: Is It Just About Going to Class?

Statins and Cardiac Surgery

Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum

Should Lipoprotein(a) be Measured in Youth?

Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics.

Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease

Complications of Progression of CKD

Not all women diagnosed with PCOS share the same cardiovascular risk profiles

Undetected Hypertension and Prehypertension in Children with Diabetes Need Attention

Are We There Yet? Pediatric Screening for Inflammatory Biomarkers and Low Cardiorespiratory Fitness to Identify Youth at Increased Risk of Cardiovascular Disease

Adverse events of upper GI endoscopy

PCSK9 has exploded onto center stage of plasma cholesterol metabolism, raising hopes for a new strategy to treat hypercholesterolemia. PCSK9 in a plasma protein that triggers increased degradation of the LDL receptor. Gain-of-function mutations in PCSK9 reduce LDL receptor levels in the liver, resulting in high levels of LDL cholesterol in the plasma and increased susceptibility to coronary heart disease. Loss-of-function mutations lead to higher levels of the LDL receptor, lower LDL cholesterol levels, and protection from coronary heart disease. Two papers in this issue of the Journal of Lipid Research exemplify the rapid pace of progress in understanding PCSK9 molecular interactions and physiology. Dr. Shilpa Pandit and coworkers from Merck Research Laboratories describe the functional basis for the hypercholesterolemia associated with gain-of-function missense mutations in PCSK9. Dr. Jay Horton's group at UT Southwestern describe the kinetics and metabolism of PCSK9 and the impact of PCSK9 on LDL receptors in the liver and adrenal gland.

Preeclampsia: Exposing Future Cardiovascular Risk in Mothers and Their Children